BMRA:NSD-Biomerica Inc (USD)

COMMON STOCK | Diagnostics & Research | NSD

Last Closing Price

USD 4.81

Change

0.00 (0.00)%

Market Cap

USD 0.06B

Volume

0.41M

Avg Analyst Target

USD 13.00 (+170.27%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, or fecal specimens from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific bacteria, hormones, antibodies, antigens, or other substances, which exist in the patient's body and stools or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, diabetes, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods, an irritable bowel syndrome therapy technology and diagnostic-guided therapy; Helicobacter pylori products, as well as develops, tests, validates, and sells diagnostic products for COVID-19 infection. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California. Address: 17571 Von Karman Avenue, Irvine, CA, United States, 92614

Company Website : http://www.biomerica.com

Address : 17571 Von Karman Avenue, Irvine, CA, United States, 92614

Employees : 66

Fiscal Year End : May

Currency: USD

Country : USA

Technical Indicators

Beta : -0.66

52 Week High : 8.15

Short Ratio : 13.04

52 Week Low : 3.30

Shorted Shares : 794,282

200 Day Moving Average : 4.32

Shorted Shares Previous Month : 974,481

50 Day Moving Average : 5.13

Shares Held By Insiders : 16.01%

Short Percentage : 6.00%

Shares Held by Institutions : 20.52%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-10-24 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ILMN Illumina Inc

N/A

 USD64.03B 78.35 54.40
IDXX IDEXX Laboratories Inc

N/A

 USD55.46B 77.71 57.14
DXCM DexCom Inc

N/A

 USD54.82B 106.14 119.10
ICLR ICON Public Limited Company

N/A

 USD22.11B 40.47 40.36
EXAS Exact Sciences Corporation

N/A

 USD16.16B N/A N/A
GH Guardant Health Inc

N/A

 USD11.08B N/A N/A
NTRA Natera Inc

N/A

 USD10.78B N/A N/A
PRAH PRA Health Sciences, Inc

N/A

 USD10.70B 50.52 25.79
SYNH Syneos Health Inc

N/A

 USD9.23B 39.79 21.13
MEDP Medpace Holdings Inc

N/A

 USD6.70B 40.32 30.30

ETFs Containing BMRA

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Diagnostics & Research)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -3.41% 55% F 35% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -3.41% 55% F 34% F
Trailing 12 Months  
Capital Gain -14.26% 39% F 19% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -14.26% 39% F 18% F
Trailing 5 Years  
Capital Gain 72.40% 51% F 61% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 72.40% 51% F 58% F
Average Annual (5 Year Horizon)  
Capital Gain 40.56% 63% D 81% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 40.56% 63% D 80% B-
Risk Return Profile  
Volatility (Standard Deviation) 79.49% 36% F 22% F
Risk Adjusted Return 51.02% 63% D 69% D+
Market Capitalization 0.06B 17% F 13% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Diagnostics & Research)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 8.07 25% F 17% F
Price / Cash Flow Ratio -11.46 75% C 73% C
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -57.23% 28% F 26% F
Return on Invested Capital -55.76% 33% F 15% F
Return on Assets -28.11% 22% F 13% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 13.04 9% F 5% F
Short Percent 7.12% 28% F 25% F
Beta -0.66 98% A+ 99% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector